IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo donor specific antibody development continues to negatively impact patients undergoing kidney transplantation. One of the recent advances in solid organ transplantation has been the definition of molecular mismatching between donors and recipients’ Human Leukocyte Antigens (HLA). While not fully integrated in standard clinical care, cumulative molecular mismatch at the level of eplets (EMM) as well as the PIRCHE-II score have shown promise in predicting transplant outcomes. In this manuscript, we sought to study whether certain T-cell molecular mismatches (TcEMM) were highly predictive of death-censored graft failure (DCGF).MethodsWe studied...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
BACKGROUND: Recently, the impact of human leukocyte antigen (HLA) mismatch (MM) on graft outcome has...
IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo...
IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo...
IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo...
IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo...
IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
Introduction: To mitigate risks related to human leukocyte antigen (HLA) incompatibility, we assesse...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
<p>Individual HLA mismatches may differentially impact graft survival after kidney transplantation. ...
HLA-mismatches in hematopoietic stem-cell transplantation are associated with an impaired overall su...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
BACKGROUND: Recently, the impact of human leukocyte antigen (HLA) mismatch (MM) on graft outcome has...
IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo...
IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo...
IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo...
IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo...
IntroductionKidney transplantation is the optimal treatment in end-stage kidney disease, but de-novo...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
Introduction: To mitigate risks related to human leukocyte antigen (HLA) incompatibility, we assesse...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
<p>Individual HLA mismatches may differentially impact graft survival after kidney transplantation. ...
HLA-mismatches in hematopoietic stem-cell transplantation are associated with an impaired overall su...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antig...
BACKGROUND: Recently, the impact of human leukocyte antigen (HLA) mismatch (MM) on graft outcome has...